Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 5/20 | 0.40 |
| ▸ | ADORA2B | P29275 | 4/20 | 0.40 |
| ▸ | PDE4A | P27815 | 3/20 | 0.38 |
| ▸ | PDE4B | Q07343 | 3/20 | 0.38 |
| ▸ | PDE4C | Q08493 | 3/20 | 0.38 |
| ▸ | PDE4D | Q08499 | 3/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | BLM | P54132 | 1/20 | 0.38 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | MITF | O75030 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4763151 | 0.93 | ALDH1A1 (0.40) | ADORA2AADORA2BPDE4APDE4BPDE4C | |
| SCHEMBL4769165 | 0.90 | PDE4A (0.39) | ADORA2AADORA2BPDE4APDE4BPDE4C | |
| SCHEMBL4763504 | 0.90 | ADORA2B (0.46) | ADORA2AADORA2BPDE4APDE4BPDE4C | |
| SCHEMBL4058512 | 0.88 | ADORA2A (0.38) | ADORA2AADORA2BPDE4APDE4BPDE4C | |
| SCHEMBL4058469 | 0.88 | KDM4E (0.42) | ADORA2AADORA2BPDE4APDE4BPDE4C | |
| SCHEMBL4057548 | 0.82 | ALDH1A1 (0.44) | ADORA2AADORA2BPDE4APDE4BPDE4C | |
| SCHEMBL4771669 | 0.82 | ALDH1A1 (0.41) | ADORA2AADORA2BPDE4APDE4BPDE4C | |
| SCHEMBL4772714 | 0.81 | ADORA2B (0.39) | ADORA2AADORA2BPDE4APDE4BPDE4C | |
| SCHEMBL8176996 | 0.81 | RGS4 (0.36) | ADORA2AADORA2BPDE4APDE4BPDE4C | |
| SCHEMBL4766301 | 0.81 | RGS4 (0.47) | ADORA2AADORA2BCYP1A2NPC1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8349848-B2 | Pyrrolo[3,2-D]pyrimidines that are selective antagonists of A2B adenosine receptors | Dogwoof Pharmaceuticals, Inc. (US) | 2013-01-08 | — | — | US | disclosed |
| US-8349848-B2 | Pyrrolo[3,2-D]pyrimidines that are selective antagonists of A2B adenosine receptors | Dogwoof Pharmaceuticals, Inc. (US) | 2013-01-08 | — | — | US | disclosed |
| US-8349848-B2 | Pyrrolo[3,2-D]pyrimidines that are selective antagonists of A2B adenosine receptors | Dogwoof Pharmaceuticals, Inc. (US) | 2013-01-08 | — | — | US | disclosed |
| US-20090082347-A1 | PYRROLO[3,2-D]PYRIMIDINES THAT ARE SELECTIVE ANTAGONISTS OF A2B ADENOSINE RECEPTORS | ADENOSINE THERAPEUTICS, LLC | 2009-03-26 | — | — | US | disclosed |
| US-20090082347-A1 | PYRROLO[3,2-D]PYRIMIDINES THAT ARE SELECTIVE ANTAGONISTS OF A2B ADENOSINE RECEPTORS | ADENOSINE THERAPEUTICS, LLC | 2009-03-26 | — | — | US | disclosed |
| US-20090082347-A1 | PYRROLO[3,2-D]PYRIMIDINES THAT ARE SELECTIVE ANTAGONISTS OF A2B ADENOSINE RECEPTORS | ADENOSINE THERAPEUTICS, LLC | 2009-03-26 | — | — | US | disclosed |
| US-7504398-B2 | potent and selective antagonists of adenosine receptors; Parkinson's disease, asthma, allergies, inflammation, atherosclerosis, hypertension, gastrointestinal disorders, cell proliferation and autoimmune diseases; sulfonamidation | LABORATORIOS ALMIRALL S.A. (ES) | 2009-03-17 | — | — | US | disclosed |
| EP-1678181-B1 | A2B ADENOSINE RECEPTOR ANTAGONISTS | CV THERAPEUTICS INC (US) | 2008-12-31 | — | — | EP | disclosed |
| US-7470697-B2 | Pyrrolo[3,2-D] pyrimidines that are selective antagonists of A2B adenosine receptors | ADENOSINE THERAPEUTICS, LLC (US) | 2008-12-30 | — | — | US | disclosed |
| US-7470697-B2 | Pyrrolo[3,2-D] pyrimidines that are selective antagonists of A2B adenosine receptors | ADENOSINE THERAPEUTICS, LLC (US) | 2008-12-30 | — | — | US | disclosed |
| EP-1678181-A2 | A2B ADENOSINE RECEPTOR ANTAGONISTS | CV THERAPEUTICS, INC. (US) | 2006-07-12 | — | — | EP | disclosed |
| WO-2006052962-A2 | BICYCLIC TRIAZOLE A4 INTEGRIN INHIBITORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2006-05-18 | — | — | WO | disclosed |
| US-20050261248-A1 | New-4-pyrrolopyrimidin-6-YL)benzenesulphonamide derivatives | LABORATORIOS ALMIRALL, S.A. (ES) | 2005-11-24 | — | — | US | disclosed |
| US-20050119287-A1 | A2B adenosine receptor antagonists | GILEAD PALO ALTO, INC. | 2005-06-02 | — | — | US | disclosed |
| WO-2005042534-A2 | A2B ADENOSINE RECEPTOR ANTAGONISTS | CV THERAPEUTICS, INC. (US) | 2005-05-12 | — | — | WO | disclosed |
| US-20050070558-A1 | 6-Phenyldihydropyrrolopyrimidinedione derivatives | ALMIRALL PRODESFARMA S.A. (ES) | 2005-03-31 | — | — | US | disclosed |
| EP-1492793-A1 | NEW-4-(PYRROLOPYRIMIDIN-6-YL)BENZENESULPHONAMIDE DERIVATIVES | Almirall Prodesfarma, S.A. (ES) | 2005-01-05 | — | — | EP | disclosed |
| EP-1409489-A1 | 6-PHENYLDIHYDROPYRROLOPYRIMIDINEDIONE DERIVATIVES | Almirall Prodesfarma, S.A. (ES) | 2004-04-21 | — | — | EP | disclosed |
| WO-2003082873-A1 | NEW-4-(PYRROLOPYRIMIDIN-6-YL)BENZENESULPHONAMIDE DERIVATIVES | ALMIRALL PRODESFARMA, S.A. (ES) | 2003-10-09 | — | — | WO | disclosed |
| WO-2003000694-A1 | 6-PHENYLDIHYDROPYRROLOPYRIMIDINEDIONE DERIVATIVES | ALMIRALL PRODESFARMA S.A. (ES) | 2003-01-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050261248-A1 | New-4-pyrrolopyrimidin-6-YL)benzenesulphonamide derivatives | ADORA2B, ADORA2A, ADORA3 | ADORA2A 2/4885ADORA2B 1/4885PDE4A 100/4885 |
| US-20050119287-A1 | A2B adenosine receptor antagonists | ADORA2B, ADORA2A, ADORA3 | ADORA2A 2/4885ADORA2B 1/4885PDE4A 182/4885 |
| US-20090082347-A1 | PYRROLO[3,2-D]PYRIMIDINES THAT ARE SELECTIVE ANTAGONISTS OF A2B ADENOSINE RECEPTORS | ADORA2B, ADORA2A, ADORA3 | ADORA2A 2/4885ADORA2B 1/4885PDE4A 320/4885 |
| US-20050070558-A1 | 6-Phenyldihydropyrrolopyrimidinedione derivatives | ADORA1, ADORA2A, P2RY10 | ADORA2A 2/4885ADORA2B 4/4885PDE4A 915/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.